10.11
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting…
In heart failure, continuous RAAS activation intensifies cardiac workload, causing fatal tissue remodeling if untreated.
Heart failure pharmacotherapy helps reduce these harmful neurohumoral effects.
Angiotensin-converting enzyme or ACE inhibitors block the conversion of Angiotensin I to II, lowering its levels and enhancing bradykinin and substance P levels.
Next, angiotensin receptor blockers or ARBs selectively antagonize AT1 receptors modulating Angiotensin II effects. They are therapeutic alternatives for ACE inhibitor-intolerant patients.
Further, mineralocorticoid receptor antagonists or MRAs block nuclear aldosterone receptors and act as K+ -sparing diuretics.
These strategies decrease peripheral resistance, cardiac afterload, and sympathetic activity while increasing natriuresis.
However, ACE inhibitors and ARBs have various adverse effects and are contraindicated in pregnancy. Additionally, ACE inhibitors can induce a dry cough, while MRAs may cause allergic reactions and gynecomastia in males.
Lastly, the pharmacotherapeutic arsenal includes β1- blockers and combination therapies of ARBs with neprilysin inhibitors.
View the full transcript and gain access to JoVE Core videos
Q1: How do ACE inhibitors help manage heart failure?
ACE inhibitors block the conversion of Angiotensin I to Angiotensin II, lowering its levels and enhancing bradykinin and substance P. This reduces peripheral resistance, cardiac afterload, and sympathetic activity while promoting vasodilation and reducing aldosterone release. These effects counteract harmful neurohumoral activation in heart failure.
Q2: What are the differences between ACE inhibitors and angiotensin receptor blockers?
ACE inhibitors block Angiotensin II formation, while angiotensin receptor blockers selectively antagonize AT1 receptors to modulate Angiotensin II effects. ARBs serve as therapeutic alternatives for patients intolerant to ACE inhibitors. Both reduce peripheral resistance and cardiac afterload, but ARBs avoid the dry cough side effect associated with increased bradykinin levels.
Q3: Why are mineralocorticoid receptor antagonists used in heart failure treatment?
Mineralocorticoid receptor antagonists block nuclear aldosterone receptors and act as potassium-sparing diuretics. They decrease peripheral resistance, cardiac afterload, and sympathetic activity while increasing natriuresis. MRAs have documented life-prolonging effects in heart failure patients by reducing fibrosis and counteracting harmful neurohumoral effects.
Q4: What adverse effects should patients expect from RAAS inhibitors?
ACE inhibitors can induce a dry cough or rare angioedema due to increased bradykinin and substance P levels. Both ACE inhibitors and ARBs are contraindicated in pregnancy and may increase hyperkalemia and renal dysfunction. Mineralocorticoid receptor antagonists may cause allergic reactions, gynecomastia in males, and dysmenorrhea.
Q5: How does sacubitril/valsartan combination therapy benefit heart failure patients?
Sacubitril/valsartan combines an ARB with a neutral endopeptidase inhibitor to activate the beneficial axis of neurohumoral activation. This combination provides multiple benefits including natriuresis, vasodilation, inhibition of thrombosis, and cardiac remodeling prevention, offering enhanced therapeutic outcomes compared to single-agent therapy.
Q6: What role do beta-blockers play in heart failure management?
Beta-blockers reduce the actions of catecholamines on beta-adrenoceptors, decreasing heart rate, contractile force, and AV conduction. They suppress arrhythmias, lower renin levels, and reduce sympathetic activity. Beta-blockers are often combined with ACE inhibitors and ARBs as part of comprehensive neurohumoral modulation therapy for heart failure.
Q7: Why is continuous RAAS activation harmful in untreated heart failure?
Continuous RAAS activation intensifies cardiac workload and causes fatal tissue remodeling if untreated. This neurohumoral activation leads to increased sympathetic activity, vasoconstriction, and aldosterone-mediated salt and water retention. RAAS inhibitors counteract these harmful effects by reducing Angiotensin II levels and blocking aldosterone signaling.